Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today ...
On Monday, H.C. Wainwright adjusted its outlook on Pyxis Oncology Inc. (NASDAQ:PYXS), reducing the price target to $5.00 from the previous $7.00, but retained a Buy rating on the stock. Currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback